Patents by Inventor Sophie Beauchemin

Sophie Beauchemin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intermediates for macrocyclic compounds
    Patent number: 10040751
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: August 7, 2018
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
    Publication number: 20160221927
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Application
    Filed: October 1, 2015
    Publication date: August 4, 2016
    Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Oullet, Carl St-Louis, Sophie Beauchemin
  • Macrocyclic ghrelin receptor modulators and methods of using the same
    Patent number: 9371297
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: June 21, 2016
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
  • Intermediates for macrocyclic compounds
    Patent number: 9181298
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: November 10, 2015
    Assignee: OCERA THERAPEUTICS, INC.
    Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark Peterson, Sylvie Beaubien, Luc Oullet, Carl St-Louis, Sophie Beauchemin
  • Processes for intermediates for macrocyclic compounds
    Patent number: 8497242
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: July 30, 2013
    Assignee: Tranzyme Pharma Inc.
    Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • Spatially-defined macrocyclic compounds useful for drug discovery
    Patent number: 8440851
    Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 14, 2013
    Assignee: Tranzyme Pharma, Inc.
    Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • Processes for Intermediates for Macrocyclic Compounds
    Publication number: 20110245459
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Application
    Filed: February 28, 2011
    Publication date: October 6, 2011
    Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY
    Publication number: 20110237785
    Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.
    Type: Application
    Filed: February 28, 2011
    Publication date: September 29, 2011
    Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
    Publication number: 20110105389
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.
    Type: Application
    Filed: October 29, 2010
    Publication date: May 5, 2011
    Inventors: Hamid R. Hoveyda, Eric Marsault, Helmut Thomas, Graeme Fraser, Sylvie Beaubien, Axel Mathieu, Julien Beignet, Marc-André Bonin, Serge Phoenix, David Drutz, Mark Peterson, Sophie Beauchemin, Martin Brassard, Martin Vezina
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Patent number: 7935825
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: May 3, 2011
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Sophie Beauchemin
  • INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
    Publication number: 20090240027
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Application
    Filed: November 19, 2008
    Publication date: September 24, 2009
    Inventors: Eric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20080194672
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: February 8, 2008
    Publication date: August 14, 2008
    Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, David Drutz, Eric Marsault, Luc Ouellet, Mark L. Peterson, Zhigang Wang
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Publication number: 20070219255
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Application
    Filed: May 4, 2007
    Publication date: September 20, 2007
    Inventors: Robert Burk, Sophie Beauchemin
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Patent number: 7214678
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: May 8, 2007
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Sophie Beauchemin
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Publication number: 20060217349
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Application
    Filed: June 1, 2006
    Publication date: September 28, 2006
    Inventors: Robert Burk, Sophie Beauchemin
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Patent number: 7098223
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: August 29, 2006
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Sophie Beauchemin
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Publication number: 20050032746
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Application
    Filed: September 10, 2004
    Publication date: February 10, 2005
    Inventors: Robert Burk, Sophie Beauchemin
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Patent number: 6825221
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: November 30, 2004
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Sophie Beauchemin
  • Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
    Publication number: 20030078236
    Abstract: According to the invention there is provided a compound the formula I; 1
    Type: Application
    Filed: August 29, 2002
    Publication date: April 24, 2003
    Applicant: Allergan, Inc.
    Inventors: Robert M. Burk, Sophie Beauchemin